Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers

Trial Profile

Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2015

At a glance

  • Drugs Suptavumab (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 09 Nov 2014 Planned End Date changed from 1 Jan 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov
    • 09 Nov 2014 Planned primary completion date changed from 1 Jan 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top